INDICATION
BESREMI is indicated for the treatment of adults with polycythemia vera

IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS DISORDERS
Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy.

CONTRAINDICATIONS
• Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt
• Hypersensitivity to interferons including interferon alfa-2b or any of the inactive ingredients of BESREMI.
• Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
• History or presence of active serious or untreated autoimmune disease
• Immunosuppressed transplant recipients

WARNINGS AND PRECAUTIONS
• Depression and Suicide: Life-threatening or fatal neuropsychiatric reactions have occurred in patients receiving interferon alfa-2b products, including BESREMI. These reactions may occur in patients with and without previous psychiatric illness.
• Other central nervous system effects, including suicidal ideation, attempted suicide, aggression, bipolar disorder, mania and confusion have been observed with other interferon alfa products.
• Closely monitor patients for any symptoms of psychiatric disorders and consider psychiatric consultation and treatment if such symptoms emerge. If psychiatric symptoms worsen, it is recommended to discontinue BESREMI therapy.
• Endocrine Toxicity: These toxicities may include worsening hypothyroidism and hyperthyroidism. Do not use BESREMI in patients with active serious or untreated endocrine disorders associated with autoimmune disease. Evaluate
thyroid function in patients who develop symptoms suggestive of thyroid disease during BESREMI (ropoeinterferon alfa-2b-ntf) injection therapy. Discontinue BESREMI in patients who develop endocrine disorders that cannot be adequately managed during treatment with BESREMI.

- **Cardiovascular Toxicity:** Toxicities may include cardiomyopathy, myocardial infarction, atrial fibrillation and coronary artery ischemia. Patients with a history of cardiovascular disorders should be closely monitored for cardiovascular toxicity during BESREMI therapy. Avoid use of BESREMI in patients with severe or unstable cardiovascular disease, (e.g., uncontrolled hypertension, congestive heart failure (≥ NYHA class 2), serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina) or recent stroke or myocardial infarction.

- **Decreased Peripheral Blood Counts:** These toxicities may include thrombocytopenia (increasing the risk of bleeding), anemia, and leukopenia (increasing the risk of infection). Monitor complete blood counts at baseline, during titration and every 3-6 months during the maintenance phase. Monitor patients for signs and symptoms of infection or bleeding.

- **Hypersensitivity Reactions:** Toxicities may include serious, acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis). If such reactions occur, discontinue BESREMI and institute appropriate medical therapy immediately. Transient rashes may not necessitate interruption of treatment.

- **Pancreatitis:** Pancreatitis has occurred in 2.2% of patients receiving BESREMI. Symptoms may include nausea, vomiting, upper abdominal pain, bloating, and fever. Patients may experience elevated lipase, amylase, white blood cell count, or altered renal/hepatic function. Interrupt BESREMI treatment in patients with possible pancreatitis and evaluate promptly. Consider discontinuation of BESREMI in patients with confirmed pancreatitis.

- **Colitis:** Fatal and serious ulcerative or hemorrhagic/ischemic colitis have occurred in patients receiving interferon alfa products, some cases starting as early as 12 weeks after start of treatment. Symptoms may include abdominal pain, bloody diarrhea, and fever. Discontinue BESREMI in patients who develop these signs or symptoms. Colitis may resolve within 1 to 3 weeks of stopping treatment.

- **Pulmonary Toxicity:** Pulmonary toxicity may manifest as dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoïdosis. Some events have resulted in respiratory failure or death. Discontinue BESREMI in patients who develop pulmonary infiltrates or pulmonary function impairment.

- **Ophthalmologic Toxicity:** These toxicities may include severe eye disorders such as retinopathy, retinal hemorrhage, retinal exudates, retinal detachment and retinal artery or vein occlusion which may result in blindness. During BESREMI therapy, 23% of patients were identified with an eye disorder. Eyes disorders ≥5% included cataract (6%) and dry eye (5%). Advise patients to be aware of their eyes and use machinery. Patients should not drive or use heavy machinery when they know how BESREMI affects their abilities. Patients who experience dizziness, somnolence or hallucination during BESREMI therapy should avoid driving or using machinery.

- **Embryo-Fetal Toxicity:** Based on the mechanism of action, BESREMI can cause fetal harm when administered to a pregnant woman. Pregnancy testing is recommended in females of reproductive potential prior to treatment with BESREMI. Advise females of reproductive potential to use an effective method of contraception during treatment with BESREMI and for at least 8 weeks after the final dose.

### ADVERSE REACTIONS

The most common adverse reactions reported in > 40% of patients in the PEGINVERA study (n=51) were influenza-like illness, arthralgia, fatigue, pruritis, nasopharyngitis, and musculoskeletal pain. In the pooled safety population (n=178), the most common adverse reactions greater than 10%, were liver enzyme elevations (20%), leukopenia (20%), thrombocytopenia (19%), arthralgia (13%), fatigue (12%), myalgia (11%), and influenza-like illness (11%).

### DRUG INTERACTIONS

Patients on BESREMI who are receiving concomitant drugs which are CYP450 substrates with a narrow therapeutic index should be monitored to inform the need for dosage modification for these concomitant drugs. Avoid use with myelosuppressive agents and monitor patients receiving the combination for effects of excessive myelosuppression. Avoid use with narcotics, hypnotics or sedatives and monitor patients receiving the combination for effects of excessive CNS toxicity.

### USE IN SPECIFIC POPULATIONS

- **Pregnancy:** Based on mechanism of action and the role of interferon alfa in pregnancy and fetal development, BESREMI may cause fetal harm and should be assumed to have abortifacient potential when administered to a pregnant woman. There are adverse effects on maternal and fetal outcomes associated with polyorchy therapy vera in pregnancy. Advise pregnant women of the potential risk to a fetus.

- **Lactation:** There are no data on the presence of BESREMI in human or animal milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children from BESREMI, advise women not to breastfeed during treatment and for 8 weeks after the final dose.

- **Females of Reproductive Potential:** BESREMI may cause embryo-fetal harm when administered to a pregnant woman. Pregnancy testing prior to BESREMI treatment is recommended for females of reproductive potential. Advise female patients of reproductive potential to use effective contraception during treatment with BESREMI and for at least 8 weeks after the final dose.

- **Pediatric Use:** Safety and effectiveness in pediatric patients have not been established.

- **Geriatric Use:** In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other therapy.

Please see [full Prescribing Information](#), including Boxed Warning.